Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GNTA | US
-0.26
-4.51%
Healthcare
Biotechnology
31/12/2023
18/10/2024
5.50
5.61
6.00
5.42
Genenta Science S.p.A. a clinical-stage biotechnology company engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. In addition it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan Italy.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
160.5%1 month
137.9%3 months
106.4%6 months
115.5%-
-
4.73
0.00
0.00
-11.48
-
-
-11.69M
100.19M
100.19M
-
-
-
-
-45.16
0.64
0.04
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.88
Range1M
3.98
Range3M
3.98
Rel. volume
2.35
Price X volume
327.96K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AVTX | AVTX | Biotechnology | 11.18 | 108.45M | 7.50% | n/a | -80.47% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 3.59 | 105.87M | 3.76% | n/a | 81.33% |
Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.35 | 103.76M | 5.47% | n/a | 0.00% |
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.9 | 103.74M | -1.04% | n/a | 9.99% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.57 | 102.78M | 3.29% | n/a | 1.45% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.675 | 102.36M | 14.81% | n/a | 0.73% |
Marinus Pharmaceuticals Inc | MRNS | Biotechnology | 1.85 | 101.91M | 6.32% | n/a | -202.54% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8829 | 101.72M | 4.09% | n/a | -354.71% |
INmune Bio Inc | INMB | Biotechnology | 5.11 | 101.34M | 2.20% | n/a | 14.65% |
Agenus Inc | AGEN | Biotechnology | 4.62 | 99.66M | 1.09% | n/a | -170.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.28 | 92.70M | 0.72% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.48 | 90.67M | 0.91% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -11.48 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 4.73 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 106.39 | 72.92 | Riskier |
Debt to Equity | 0.00 | -1.24 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 100.19M | 3.78B | Emerging |